HC Wainwright & Co. Maintains Buy Rating for LifeMD: Here's What You Need To Know
Portfolio Pulse from Benzinga Insights
HC Wainwright & Co. has maintained its Buy rating for LifeMD (NASDAQ:LFMD) and increased its price target from $9.00 to $10.00. LifeMD shares are currently trading up 3.07% at $7.38 per share. A move to $10.00 would represent a 35.5% increase from the current share price.
November 09, 2023 | 5:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
LifeMD's stock price may increase in the short term due to the maintained Buy rating and increased price target by HC Wainwright & Co.
Analyst ratings often influence investor sentiment and can impact stock prices. In this case, HC Wainwright & Co. has maintained a Buy rating for LifeMD and increased its price target, which suggests a positive outlook for the company's stock. This could lead to increased investor interest and a potential rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100